ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs (DECLARE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00300573
Recruitment Status : Terminated (Development program ended due to inability to pair with other cytidine analogs and higher risk of hyperlipasemia when not used with 3TC/FTC.)
First Posted : March 9, 2006
Last Update Posted : June 4, 2012
Sponsor:
Information provided by (Responsible Party):
Incyte Corporation

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Primary Completion Date : No date given
  Actual Study Completion Date : April 2006